GLSI

GLSI

Greenwich Lifesciences Inc

Rev —top 1%5Y
Hold

Greenwich LifeSciences develops immunotherapies targeting breast cancer, particularly for HER2/neu-expressing cancers. Its lead candidate, GP2, is in Phase III trials to prevent recurrences in patients post-surgery, alongside the FLAMINGO-01 study.

⚕️ Healthcare NASDAQ Listed 2020 $ USD
$1,000 invested 5 years ago $413today

Score Overview

1 Year
Score
Net Growth
Net Trend
Net Income Consistency
Rev Growth
Rev Trend
Revenue Consistency
5 Years
Score
Net Growth-241.04%
Net TrendNever
Net Income Consistency
Rev Growth
Rev TrendNever
Revenue Consistency
All Time
Score
Net Growth-6x
Net TrendNever
Net Income Consistency
Rev Growth
Rev TrendNever
Revenue Consistency

See the full market ranking →

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-08-12
$ 16.92
1 Year2025-08-12
$ 12.3537.00%
5 Years2021-08-12
$ 41.00-58.73%
All Time2020-09-25
$ 5.00238.40%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Year
2026$ 7.17K-$ 15M
2025-$ 6M
2024$ 0.00-$ 15M$ 4M
2023$ 0.00-$ 8M$ 6M
2022$ 0.00-$ 7M$ 13M
2021$ 0.00-$ 4M$ 27M
IPO2020$ 0.00-$ 1M$ 28M

Explore beyond GLSI

You're looking at Greenwich Lifesciences Inc. Members apply the same fundamental framework across all 3,860 companies we cover.

$99/year $149 founding price

Unlock Holder Dashboard

30-day money-back guarantee.

Explore other companies